Astec LifeSciences First Quarter 2025 Earnings: Misses Expectations

Astec LifeSciences (NSE:ASTEC) First Quarter 2025 Results

Key Financial Results

• Revenue: ₹703.0m (down 51% from 1Q 2024).
• Net loss: ₹397.2m (loss widened by 385% from 1Q 2024).
• ₹20.26 loss per share (further deteriorated from ₹4.18 loss in 1Q 2024).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Astec LifeSciences Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 5.3%. Earnings per share (EPS) also missed analyst estimates by 60%.

Looking ahead, revenue is forecast to grow 43% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Chemicals industry in India.

Performance of the Indian Chemicals industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

It is worth noting though that we have found 1 warning sign for Astec LifeSciences that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com